Eli Lilly and Co., of Indianapolis, disclosed phase III data showing ixekizumab was statistically superior to etanercept (Enbrel, Amgen Inc.) and placebo on all skin clearance measures in pivotal phase III studies comparing the drugs in moderate to severe plaque psoriasis.